Media Center

Press releases

Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million

Alfasigma signs an agreement to acquire Jyseleca® business for up to €170 million from Galapagos following October letter of intent

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.

Alfasigma signs a letter of intent to acquire the Jyseleca® business from Galapagos, expanding its European presence through an innovative product specializing in the rheumatology and gastrointestinal areas

Alfasigma S.p.A. tender offer for Intercept Pharmaceuticals, Inc. commences

Press release archive

Multimedia

Social Wall

Press coverage

Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market

Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Devel...

Interview with Stefano Golinelli by Margherita Lopes - Adnkronos Salute’s PharmaKronos

Press coverage archive
×

You’re entering Alfasigma global website

I agree